This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
payments: Archive
Can Global Payments Navigate Through Rising Costs in Q4 Earnings?
by Zacks Equity Research
GPN's fourth-quarter earnings are likely to have benefited from growing revenues from Americas and Europe operations.
MAPositive Net Change FISNegative Net Change WUNegative Net Change GPNNegative Net Change
business-services earnings finance payments
Mastercard's Q4 Win & Services Boom: Time to Buy or Take Profits?
by Kaibalya Pravo Dey
MA's security, digital authentication and pricing strategies continue to strengthen its value-added services segment.
MAPositive Net Change VPositive Net Change AXPNegative Net Change
business-services earnings-report earnings-surprise finance payments
Visa's Q1 Triumph & AI Strength: Should Investors Still Buy the Stock?
by Kaibalya Pravo Dey
Through strategic diversification, innovation, and AI-driven security, V is well-positioned for long-term growth.
MAPositive Net Change VPositive Net Change AXPNegative Net Change
business-services earnings-outlook earnings-report earnings-surprise finance payments
Strong Q4 Has AmEx Bulls Charging: Should You Join Them Now?
by Kaibalya Pravo Dey
AXP has seen its earnings estimates for 2025 and 2026 move north over the past month.
MAPositive Net Change AXPNegative Net Change SYFPositive Net Change
earnings-estimates-revisions earnings-outlook earnings-report earnings-surprise finance payments
TAL Education (TAL) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TALPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
World Acceptance (WRLD) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
WRLDPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Weekly Option Windfall: Trading AXP Options Following Q4 Earnings Beat
by Bryan Hayes
One of Warren Buffett's long-held positions, American Express just delivered its fourth consecutive earnings beat.
AXPNegative Net Change
consumer-discretionary earnings finance large-cap options payments travel-leisure
Should You Buy Blueprint Medicines (BPMC) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Pacira (PCRX) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PCRXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Affirm Q2 Earnings Incoming: Time to Buy, Sell, or Hold the Stock?
by Kaibalya Pravo Dey
AFRM's fiscal second-quarter results are likely to reflect growing GMV and transactions.
VPositive Net Change PYPLNegative Net Change AFRMPositive Net Change
business-services earnings-outlook earnings-preview finance payments
Pre-Markets Flat Ahead of JOLTS; Q4 Earnings for PFE, PYPL, PEP & More
by Mark Vickery
Pfizer (PFE) put up its most impressive quarterly numbers in recent memory today.
ADPNegative Net Change PFENo Net Change MRKPositive Net Change PEPNegative Net Change PYPLNegative Net Change
consumer-discretionary e-commerce earnings payments pharmaceuticals
Mastercard Q4 Earnings Beat Estimates on GDV & Transactions Growth
by Zacks Equity Research
MA estimates adjusted net revenues to witness low-double-digit growth in 2025 from the 2024 figure.
MAPositive Net Change FISNegative Net Change AFRMPositive Net Change SEZLPositive Net Change
business-services earnings finance payments
Visa & Elon Musk's X: A Power Play in the Race for Fintech Dominance?
by Kaibalya Pravo Dey
As X Money integrates with Visa Direct, millions of X users could start using Visa's network, driving up transaction volume and fees.
MAPositive Net Change VPositive Net Change TSLAPositive Net Change PYPLNegative Net Change
business-services creator-economy fin-tech finance payments social-media
Grupo Aeroportuario del Centro Norte (OMAB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
OMABPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
UiPath (PATH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PATHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is Mastercard Stock a Buy Before Q4 Earnings? Check Key Estimates
by Kaibalya Pravo Dey
MA's fourth-quarter earnings are likely to have benefited from growing GDV and switched transactions.
MAPositive Net Change VPositive Net Change AXPNegative Net Change
business-services earnings-outlook earnings-preview finance payments
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
VORNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Key Predictions for Visa's Q1 Earnings: Should You Buy the Stock Now?
by Kaibalya Pravo Dey
V's fiscal first-quarter earnings are likely to have benefited from growth in processed transactions and payment volumes.
MAPositive Net Change VPositive Net Change AXPNegative Net Change
business-services earnings-outlook earnings-preview finance payments
Adidas AG (ADDYY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ADDYYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Can Synchrony Beat Q4 Earnings Estimates on Improving Efficiency?
by Zacks Equity Research
SYF is likely to have gained from rising digital sales volume in the fourth quarter.
SYFPositive Net Change OMFPositive Net Change BFHPositive Net Change RITMPositive Net Change
earnings finance payments
American Express' Q4 Earnings Coming Up: Buy, Hold or Sell the Stock?
by Kaibalya Pravo Dey
AXP is likely to have witnessed a rise in network volumes during the fourth quarter, continuing the trend seen in the past quarters.
MAPositive Net Change VPositive Net Change AXPNegative Net Change
earnings-outlook earnings-preview finance payments pe-ratio
Pre-Markets Start Trading Week in the Green
by Mark Vickery
As Davos parses the incoming Trump administration's vast policy changes, DHI and SCHW outperform quarterly estimates.
UALPositive Net Change NFLXNegative Net Change COFPositive Net Change SCHWPositive Net Change DHINegative Net Change
banking earnings finance home-builder payments
Does Affirm's Expansionary Moves Make it a Smart Buy for Now?
by Kaibalya Pravo Dey
While AFRM's expansion into the U.K. market and its strategic alliances signal growth potential, investors should keep and eye on the challenges in a competitive and evolving BNPL landscape.
MAPositive Net Change VPositive Net Change PYPLNegative Net Change AFRMPositive Net Change
business-services finance payments
Should You Buy Mastercard at Current Valuation or Hold Off for Now?
by Kaibalya Pravo Dey
MA's digital strategy and expansion in emerging markets like Southeast Asia and Latin America will support its long-term growth.
MAPositive Net Change VPositive Net Change AXPNegative Net Change
business-services finance payments
After Golden Cross, Coterra Energy (CTRA)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CTRANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines